Literature DB >> 10737490

Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin.

B C Leibovich1, D E Engen, D E Patterson, T M Pisansky, E E Alexander, M L Blute, E J Bergstralh, H Zincke.   

Abstract

PURPOSE: Positive surgical margins are common after radical prostatectomy, and the role of adjuvant therapy in such cases is controversial. We determined the benefit of postoperative external beam radiation therapy in patients with margin positive prostate cancer with respect to biochemical progression or cancer recurrence. To decrease confounding factors that may affect the likelihood of biochemical progression our study was limited to men with organ confined cancer and a single positive margin.
MATERIALS AND METHODS: We retrospectively evaluated the records of a nested matched cohort of 76 patients with pathological stage T2N0 prostate cancer and a single positive margin who underwent adjuvant radiation therapy within 3 months of radical prostatectomy. There was a positive margin at the prostatic apex in 35 cases, prostatic base in 18, posterior prostate in 11, urethra in 7, and prostatic apex and urethra in 5. These patients were matched 1:1 with 76 controls who did not receive adjuvant radiation therapy. Neither group received androgen deprivation therapy. Patients and controls were matched exactly for the margin positive site, age at surgery, preoperative serum prostate specific antigen, Gleason score and DNA ploidy. Biochemical relapse was defined as posttreatment PSA greater than 0.2 ng./ml.
RESULTS: Overall there was significant estimated improvement plus or minus standard error in 5-year clinical and biochemical progression-free survival in 88%+/-5% versus 59%+/-11% of patients treated with adjuvant radiation therapy versus no radiation therapy (p = 0.005). No patient who received radiation therapy had local or distant recurrence, while 16% of controls had recurrence (p = 0.015). When stratified by site of margin positivity, the 5-year estimated clinical and biochemical progression-free rate in 18 cases and controls with a positive base margin was 95%+/-15% and 65%+/-13%, respectively (p = 0.02). The rate in 35 cases and cases with a positive apex margin was 95%+/-5% and 64%+/-15%, respectively (p = 0.07). Limited sample size precluded analysis of the other sites.
CONCLUSIONS: Patients with localized prostate cancer and a singe positive surgical margin appear to have a lower rate of biochemical relapse at 5 years when adjuvant radiation therapy is administered. Definitive evidence of the beneficial effect of adjuvant radiation therapy for patients with involved surgical margins awaits conclusion of randomized clinical trials.

Entities:  

Mesh:

Year:  2000        PMID: 10737490

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

Review 1.  [Organ-limited prostate cancer with positive resection margins. Importance of adjuvant radiation therapy].

Authors:  D Porres; D Pfister; B Brehmer; A Heidenreich
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

Review 2.  Percutaneous radiotherapy for low-risk prostate cancer: options for 2007.

Authors:  Dirk Bottke; Thomas Wiegel
Journal:  World J Urol       Date:  2007-02-15       Impact factor: 4.226

3.  Addressing the needs of the high-risk prostate cancer patient.

Authors:  Leonard G Gomella
Journal:  Rev Urol       Date:  2005

4.  Urethroplasty after radiation therapy for prostate cancer.

Authors:  Allison S Glass; Jack W McAninch; Uwais B Zaid; Nadya M Cinman; Benjamin N Breyer
Journal:  Urology       Date:  2012-04-21       Impact factor: 2.649

5.  High-risk, clinically localized prostate cancer: is monotherapy adequate?

Authors:  Mark H Katz; James M McKiernan
Journal:  Rev Urol       Date:  2007

6.  A Recursive Partitioning Analysis Demonstrating Risk Subsets for 8-Year Biochemical Relapse After Margin-Positive Radical Prostatectomy Without Adjuvant Hormone or Radiation Therapy.

Authors:  Steven N Seyedin; John M Watkins; Zachary Mayo; Anthony N Snow; Michael Laszewski; J Kyle Russo; Sarah L Mott; Chad R Tracy; Mark C Smith; John M Buatti; Joseph M Caster
Journal:  Adv Radiat Oncol       Date:  2021-08-14

Review 7.  What is the possible role of PSA doubling time (PSADT) and PSA velocity (PSAV) in the decision-making process to initiate salvage radiotherapy following radical prostatectomy in patients with prostate cancer?

Authors:  Piotr Milecki; Andrzej Antczak; Piotr Martenka; Zbigniew Kwias
Journal:  Cent European J Urol       Date:  2011-06-02

Review 8.  The role of postoperative radiotherapy in prostate cancer patients.

Authors:  Małgorzata Zarzycka; Ewa Ziółkowska; Tomasz Wiśniewski; Wiesława Windorbska; Agnieszka Zyromska; Zbigniew Wolski
Journal:  Contemp Oncol (Pozn)       Date:  2013-10-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.